佩奥诺尔通过抑制铁灭菌来改善血管酶II诱导的心脏缩
Canzhang Liu1, Xin Yi1, Jie Yan1
1Department I of Cardiovasology, North China University of Science and Technology Affiliated Hospital, Tangshan City, Hebei Province, 063000, PR China.
Heliyon
|September 4, 2023
概括
醇 (Pae) 通过减少心肌细胞大小和改善心脏功能来保护小鼠的心脏缩. 它通过上调xCT和GPX4蛋白质来对抗血管激素II (AngII) 诱导的铁亡.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 细胞病理学细胞病理学
背景情况:
- 心脏缩是心力衰竭的重要危险因素.
- ангиотензин II (AngII) 是心脏缩发展的一个关键调解剂.
- 铁,一种依赖铁的细胞死亡途径,在心脏损伤中起作用.
研究的目的:
- 在小鼠模型中研究埃 (Pae) 对抗AngII诱导的心脏缩的保护作用.
- 阐明帕埃诺尔心脏保护作用的潜在机制,重点关注铁亡.
主要方法:
- 构建动脉素II (AngII) 诱导的心脏缩的小鼠模型.
- 用醇 (Pae) 治疗和通过超声波评估心脏功能.
- 测量心肌细胞表面积,脂质过氧化,活性氧物种 (ROS) 和Fe2+水平.
- 对xCT和GPX4.4的线粒体形态和蛋白质表达的分析.
主要成果:
- AngII显著增加了心肌细胞表面积和心脏功能受损.
- 佩治疗显著减少了心肌细胞大小,改善了心脏功能.
- AngII提高了Fe2+,脂质过氧化物,MDA和ROS水平,而Pae治疗逆转了这些变化.
- AngII降低了xCT和GPX4蛋白质水平;Pae治疗提高了它们的调节,表明减少了铁亡.
结论:
- 醇显示出对抗AngII诱导的心脏缩的显著心脏保护作用.
- 醇通过上调xCT和GPX4.4的调节,减轻心肌细胞中AngII诱导的铁亡.
- 帕埃诺尔代表了治疗心脏缩和相关心脏病的潜在治疗剂.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
200
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
200
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
202
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
202
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
689
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
689
01:16Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K